Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rachael D. Migler
Observed institution:
Rockefeller University
ORCID:
0009-0007-9808-1820
Observed ORCID:
0009-0007-9808-1820
OpenAlex ID:
A5048745658
Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
2022
·
Krista Y. Chen
, Aleksandra Popovic
, et al.
·
Cancers
·
35
PDF
Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
2022
·
Bassem Shebl
, Denise Ng
, et al.
·
JCI Insight
·
28
PDF
Clinical and demographic predictors of survival for fibrolamellar carcinoma patients—A patient community, registry‐based study
2022
·
Amichai Berkovitz
, Rachael D. Migler
, et al.
·
Hepatology Communications
·
12
PDF
Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma
2023
·
Solomon N. Levin
, Michael D. Tomasini
, et al.
·
Science Advances
·
10
PDF
Abstract 6729: Urea cycle metabolism is disturbed in Fibrolamellar carcinoma
2023
·
Mahsa Shirani
, Solomon Levin
, et al.
·
Cancer Research
Abstract 2495: Clinical and demographic predictors of survival for fibrolamellar hepatocellular carcinoma patients - A patient-community registry-based study
2022
·
Amichai Berkovitz
, Rachael D. Migler
, et al.
·
Cancer Research
Abstract 4353: The Fibrolamellar Registry: A patient-based medical registry can address medical care
2020
·
Julie Latone Newcomb
, Siobhan Lett
, et al.
·
Cancer Research
Abstract 3357: The fibrolamellar registry: A model for the study of rare diseases
2019
·
Michelle Desmond
, Julie Latone
, et al.
·
Cancer Research
Abstract 3357: The fibrolamellar registry: A model for the study of rare diseases
2019
·
Michelle Desmond
, Julie Latone
, et al.
Show more works
View as search
Works count:
9
Citation count:
85
H-index:
4
I10-index:
4
Year
Topic
Type
